Hepatocyte Growth Factor Prevented High-Fat Diet-Induced Obesity and Improved Insulin Resistance in Mice

Jun Muratsu1,2, Masaaki Iwabayashi1, Fumihiro Sanada1, Yoshiaki Taniyama1,2, Rei Otsu1, Hiromi Rakugi2 & Ryuichi Morishita1

Obesity and its associated chronic inflammation in adipose tissue initiate insulin resistance, which is related to several pathologies including hypertension and atherosclerosis. Previous reports demonstrated that circulating hepatocyte growth factor (HGF) level was associated with obesity and type 2 diabetes. However, its precise role in obesity and related-pathology is unclear. In this experiment, cardiac-specific over-expression of human HGF in mice (HGF-Tg mice) which showed 4–5 times higher serum HGF levels than wild-type mice were used. While body weight in wild-type mice fed with high fat diet (HFD) for 14 weeks was significantly increased accompanied with insulin resistance, HGF-Tg mice prevented body weight gain and insulin resistance. The accumulation of macrophages and elevated levels of inflammatory mediators in adipose tissue were significantly inhibited in HGF-Tg mice as compared to wild-type mice. The HFD-induced obesity in wild-type mice treated with HGF-neutralizing antibody showed an exacerbated response to the glucose tolerance test. These gain-of-function and loss-of-function studies demonstrated that the elevated HGF level induced by HFD have protective role against obesity and insulin resistance.

The rising prevalence of obesity is increasingly recognized as a global pandemic that threatens the health of millions of people in both developed and developing countries. Obesity causes, or is closely linked to a large number of health conditions, including type 2 diabetes, hypertension, and cardiovascular disease, as well as non-metabolic derangements such as bone fragility and cancer. Several lines of evidence support the assumption that chronic inflammation in visceral adipose tissue (but not subcutaneous adipose tissue) is the major contributor in causing insulin resistance and metabolic syndrome in the obese population. Excess lipid accumulation in peripheral organs such as mesenteric fat tissue, skeletal muscle, and the liver causes macrophage accumulation and inflammatory cytokine release, which devolve into a vicious cycle and impair systemic insulin sensitivity. One previous report documented that circulating hepatocyte growth factor (HGF) level was associated with the incidence of obesity and type 2 diabetes. Given that HGF increases glucose uptake in adipose tissue and skeletal muscle cells and promotes β cell proliferation and survival, the increase in circulating HGF levels is likely to be a compensatory mechanism against insulin resistance in these patients, although its precise mechanism remains unknown. Thus, in this study, we examined whether increased serum HGF is devil or angel for obesity and insulin resistance. We previously established cardiac-specific over-expression of human HGF gene in mice (HGF-Tg mice) whose serum HGF levels are 4–5 times higher than in wild-type mice (WT). We chose cardiac specific HGF overexpression, as other strain of HGF transgenic mice such as liver and kidney specific HGF overexpression mice develop cancer and cystic diseases, which are rare in the heart. In the present study, using HGF-Tg mice and anti-HGF neutralizing antibody (HGF-Ab), we explored the role of HGF in obese and insulin resistance induced by HFD.

1Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. 2Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. Jun Muratsu, Masaaki Iwabayashi and Fumihiro Sanada contributed equally to this work. Correspondence and requests for materials should be addressed to Y.T. (email: taniyama@cgt.med.osaka-u.ac.jp) or R.M. (email: morishit@cgt.med.osaka-u.ac.jp)
Results

Changes in body weight in HGF-Tg mice. Body weight was measured for 14 weeks in WT and HGF-Tg mice fed with normal chow diet (ND) or high fat diet (HFD). With ND, there were no significant changes in body weight between WT and HGF-Tg mice. In contrast, body weight in HGF-Tg mice with HFD was significantly lower than those in WT mice (Fig. 1A). Similarly, increased in gonadal white adipose tissue (gWAT) weight by HFD were significantly smaller in HGF-Tg mice with HFD than those in WT mice (Fig. 1B). Intriguingly, HGF-Tg mice tended to eat more food than WT mice (Fig. 1C), and showed a significant higher level in water intake as compared to WT mice (Fig. 1D). Lipid levels such as low-density lipoprotein cholesterol, triglyceride, and free fatty acids were not different among mice, while the serum high-density lipoprotein cholesterol levels were significantly increased in HGF-Tg mice compared to WT mice following 14 weeks of HFD consumption (Figure S1).

Glucose and insulin tolerance tests for HGF-Tg mice under ND and HFD. To better understand the metabolic profile in HGF-Tg mice, we measured glucose and insulin levels. With ND, HGF-Tg mice exhibited slightly higher serum glucose and insulin levels (Fig. 2A–C). Despite these increased circulating glucose and insulin levels, IPGTT (2 g per kg intraperitoneally (i.p.)) showed that HGF-Tg mice were able to clear glucose from the blood at least as efficiently as WT mice (Fig. 2D and E). These data indicated that HGF-Tg mice would maintain normal glucose tolerance despite of higher basal glucose levels. In fact, when mice were injected with a fixed dose of insulin (0.75 U per kg i.p.; IPITT), HGF-Tg mice exhibited a similar glucose profile as WT mice, which is indicative of normal insulin sensitivity (Fig. 2F).

On the other hand, following 14 weeks of HFD, HGF-Tg mice demonstrated lower insulin levels compared to WT mice, while serum glucose level was not differed between HGF-Tg mice and WT mice (Fig. 3A–C). IPGTT showed that HGF-Tg mice exhibited lower glucose levels at 30 and 60 minutes as compared to WT mice (Fig. 3D and E). IPITT also showed better hypoglycemic response in HGF-Tg mice, suggesting superior insulin sensitivity of insulin-responsive tissue (Fig. 3F).

HGF neutralization by antibodies causes insulin resistance. To further clarify the role of endogenous HGF we examined the effects of HGF neutralizing antibody (HGF-Ab) on WT mice fed with HFD, since HGF is a well-known pleiotropic cytokine originally identified as a potent mitogen for hepatocytes. Until now, we and other groups have documented its angiogenic, anti-inflammatory, and anti-senescence properties. Unfortunately, although two systemic HGF knockout mouse models have been reported, both mice exhibited the developmental abnormalities resulting in embryonic lethality. Thus, HGF-Ab (200 µg or 400 µg) was intraperitoneally injected weekly for 12 weeks. The body weight of mice administered with 400 µg HGF-Ab was slightly increased as compared to saline group (Fig. 4A and B). Mice injected with either dose of HGF-Ab exhibited...
Figure 2. Glucose insulin tolerance of WT and HGF-Tg mice during ND consumption. (A–F) WT and HGF-Tg mice at 8 weeks of age were analyzed. (A–C) Blood glucose levels under fed conditions were significantly higher in HGF-Tg mice than in WT mice (A), although the plasma insulin levels were similar in both groups (B and C). *P < 0.05 vs. WT group. N = 4. (D and E) IPGTT performed in 8-week-old male WT and HGF-Tg mice. N = 4. *P < 0.05 vs. WT group. (F) The IPITT was comparable in WT and HGF-Tg mice fed an ND. N = 4.

Figure 3. Glucose insulin tolerance of WT and HGF-Tg mice during HFD consumption. (A–F) WT and HGF-Tg mice fed an HFD were analyzed. (A) Although the blood glucose levels were comparable between the WT and HGF-Tg mice, the blood insulin level (B and C) was significantly lower in HGF-Tg mice than in WT mice. (D and E) IPGTT in WT and HGF-Tg mice following 14 weeks of HFD consumption. *P < 0.05 vs. WT group. N = 3–5. (F) IPITT was comparable in the WT and HGF-Tg mice fed an HFD. *P < 0.05 vs. WT group. N = 3–4.
higher fasting glucose and insulin levels (Fig. 4C–E). Although no significant difference among the saline and HGF-Ab groups was observed in the IPGTT (Fig. 4F), IPITT revealed restored insulin-sensitivity in HGF-Ab 400 µg group as compared to saline group (Fig. 4G). These data indicate the existence of more pronounced insulin resistance in HGF-Ab group than saline group, which in turn implies the protective role of HGF on glucose metabolism during HFD consumption.

HGF-Tg mice prevented HFD-induced adipose tissue inflammation. Next, we investigated the mechanism how HGF prevented HFD-induced obesity and insulin resistance. Insulin resistance in obesity arises from the combination of altered functions of insulin target cells (e.g., liver, skeletal muscle, and adipose tissue) and the accumulation of macrophages that secrete pro-inflammatory mediators in adipose tissue25–28. In the gW AT, the mRNA levels of the mature macrophage marker F4/80, the chemoattractants, MCP-1 and CXCL2, and the inflammatory cytokines, such as TNF-α and iNOS, were significantly increased in WT mice fed with HFD. However, these levels were markedly reduced in HGF-Tg mice fed with HFD (Fig. 5A–F). There were no significant differences in adiponectin and its receptor expression among the groups (Fig. 5G and H ). Additionally, activation of Akt by insulin administration was significantly reduced in the gW AT SM, and liver by HFD; however, this activation was restored in HGF-Tg mice (Fig. 5I and J). Moreover, insulin-induced Akt signaling was decreased in HGF-Ab groups as compared to saline group under HFD condition (Figure S2). Importantly, as shown in Figure S3, HFD significantly increased the level of HGF mRNA by approximately 2 fold in gWAT, SM, and liver without changing cMet expression. All together, these data indicate that the HGF as one of the systemic gWAT, SM, and liver-derived growth factor plays a role in compensatory mechanism against insulin-resistance through the at least anti-inflammatory effect in adipose tissue.

Discussion
The association of obesity with type 2 diabetes is well known, and the fundamental aspect of this link is the ability of obesity to induce systemic insulin resistance25–28. Obesity-associated insulin resistance is a major risk factor for type 2 diabetes, and is also related to a wide array of other pathophysiological abnormalities including hypertension, hyperlipidemia, atherosclerosis, and metabolic syndrome. Although there has been an explosive increase in our understanding of insulin resistance in obese individuals, many details regarding the mechanisms of what causes or improves insulin resistance remain largely unknown.

Figure 4. Loss of HGF function exacerbates HFD-induced insulin resistance. (A–G) Either HGF neutralizing antibody (200 or 400 µg/week) or saline was injected into WT mice fed an HFD. (A and B) Body weight was measured weekly throughout the experiment. The BW at 12 weeks is shown (B). *P < 0.05 vs. saline group. N = 5–6. (C and D) Blood glucose levels under fasting conditions were significantly higher in the HGF-Ab groups than the saline group. N = 4. *P < 0.05 vs. WT HFD group. (E) Plasma insulin levels under fasting conditions were significantly higher in the mice injected with 400 µg HGF-Ab than in saline-injected mice. *P < 0.05 vs. saline group. N = 4. (F) IPGTT. N = 4–6 (G) IPITT. N = 4–5. *P < 0.05 vs. saline group.
The concentration of serum HGF is elevated in obese, and is correlated with serum insulin levels and body mass index. HGF secretion from the insulin target organ, such as adipocytes, liver, and skeletal muscle of obese subjects is remarkably higher than that from a healthy lean individual. In this experiment using neutralizing antibody against HGF and HGF-Tg mice, we asked whether increased serum HGF is benign or malign factor for obesity and insulin resistance. We identified the following: 1) HGF expression was increased in insulin target organ, such as liver, SM, and gW AT, in WT mice fed an HFD, and inhibition of HGF by antibody exacerbated HFD-induced obesity, insulin resistance, and impaired insulin signaling. These data suggest the HGF as the systemic growth factors plays a role in insulin-resistance compensatory mechanism. However, this compensatory mechanism is insufficient to prevent adipose tissue inflammation and obesity; 2) Additional HGF over expression observed in HGF-Tg mice inhibited HFD-induced obesity and insulin resistance, accompanied by significant changes in inflammatory mediators and insulin signaling in adipose tissue and liver.

**Figure 5.** HGF inhibits adipose tissue inflammation and enhances insulin sensitivity. (A–H) The expression of inflammatory mediators in gWAT in WT mice consuming either an ND or HFD as well as WT mice treated with HGF-Tg. *P < 0.05 vs. WT ND and HGF-Tg ND groups. **P < 0.01 vs. WT HFD group. N = 6–8. (I,J) p-Akt levels of the liver, SM, and gWAT following insulin injection. *P < 0.05 vs. corresponding insulin - group, **P < 0.05 vs. WT ND insulin + group, †P < 0.05 vs. WT HFD insulin + group. N = 4.
reduction of inflammation in gWAT. Consistently, our previous experiment has demonstrated that HGF attenuated MCP-1 and TNF-α expression of mature macrophage and inhibited hypertrophy of adipocyte in ApoE KO/ HGF-Tg mice fed with HFD, which were treated with angiotensin II. Thus, HGF is a strong anti-inflammatory growth factor in adipose tissue, and as a consequence, HGF could prevent HFD-induced obesity and systemic insulin resistance. Of note, HGF exerts a pleiotropic action on metabolic disorder. HGF increases glucose uptake in skeletal muscle and skeletal muscle specific HGF overexpression improved whole-body glucose tolerance independently of changes in body weight or plasma triglyceride levels through phosphorylated protein kinase B.

In liver, the HGF-cMet axis stimulates hepatic glucose uptake and suppresses hepatic glucose output by directly engaging insulin receptor to form a Met-Insulin receptor hybrid complex. This HGF-cMet system restores insulin responsiveness in a ob/ob mouse. Interestingly, with HFD our HGF-Tg mice significantly increased FGF 21 expression in liver and serum (data not shown), which is known to increase energy expenditure through PGC-1α and browning of white adipose tissue. Indeed, HGF-Tg mice showed higher insulin and glucose levels (Fig. 2A–C) with more food and water intake compared to WT mice (Fig. 1C and D), suggesting higher energy consumption. Definitely, pleiotropic action on insulin targeting organ is involved in the protective role of HGF on HFD-induced obesity and insulin resistance.

Another important perspective from this study is that certain pharmaceutical strategies that target insulin resistance could enhance HGF expression in adipose tissue, arteries, and skeletal muscle. For instance, the PPAR gamma agonists pioglitazone, irbesartan and telmisartan often used to treat patients with insulin resistance bind to and stimulate the HGF promoter to increase its expression in several organs. Cilostazol, a PDE-3 inhibitor, improves insulin resistance and increases HGF expression through the PPAR gamma and cAMP pathway. These drugs would have the potential to provide the additional beneficial properties (i.e., anti-inflammatory and anti-oxidative) through cilostazol's own pharmacologic targets in metabolic syndrome.

Overall, our gain-of-function study using HGF-Tg mice and loss-of-function study using anti-HGF antibody revealed that HGF prevented HFD-induced obese and systemic insulin resistance by inhibiting the inflammatory response in adipose tissue in mice. These unique character of HGF would provide us to consider new therapeutic options to treat metabolic syndrome.

Materials and Methods

All experimental procedures were reviewed and approved by the Institutional Animal Committee at the Department of Veterinary Science of Osaka University School of Medicine and follow the recommendations of the guidelines for animal experimentation at research institutes (Ministry of Education, Culture, Sports, Science and Technology, Japan), guidelines for animal experimentation at institutes (Ministry of Health, Labor and Welfare, Japan), and guidelines for proper conduct for animal experimentation (Science Council of Japan). Male C57BL6 and HGF-Tg mice aged 8–10 weeks were used. Reagents, antibodies, and primers information are described in the online-only Data Supplement.

References

1. Ng, M. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 384, 766–81 (2014).
2. Tchernof, A. & Despres, J. P. Pathophysiology of human visceral obesity: an update. Physiol Rev. 93, 359–404 (2013).
3. Vazquez, G., Duval, S., Jacobs, D. R. Jr & Silventoinen, K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiol Rev. 29, 115–28 (2007).
4. Fabbrini, E., Sullivan, S. & Klein, S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 51, 679–89 (2010).
5. Kawai, M., de Paula, F. J. & Rosen, C. J. New insights into osteoporosis: the bone-fat connection. J Intern Med. 272, 225–37 (2012).
6. Després, J. P. Body fat distribution and risk of cardiovascular disease: an update. J Intern Med. 268, 261–8 (2010).
7. Garcia-Ocaña, A. et al. Hepatocyte growth factor induces glucose uptake in 3T3-L1 adipocytes through a Gab1/phosphatidylinositol 3-kinase/Glut4 pathway. J Biol Chem. 282, 10325–32 (2007).
8. Perdomo, G. et al. Hepatocyte growth factor is a novel stimulator of glucose uptake and metabolism in skeletal muscle cells. J Biol Chem. 283, 13700–6 (2008).
9. Garcia-Ocaña, A. et al. Hepatocyte growth factor overexpression in the islet of transgenic mice increases beta cell proliferation, enhances islet mass, and induces mild hypoglycemia. J Biol Chem. 275, 1226–32 (2000).
10. Sakata, H. et al. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ. 7, 1513–1523 (1996).
11. Takayama, H. et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 94, 701–706 (1997).
12. Nakamura, T., Teramoto, H. & Ichihara, A. Purification and characterization of a growth factor from rat platelets for mature peritoneal macrophages. Proc. Natl Acad. Sci. USA 83, 6489–6493 (1986).
13. Morishita, R. et al. Safety evaluation of clinical therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension. 44, 203–209 (2004).
14. Hotta, T. et al. Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler. Thromb. Vasc. Biol. 22, 2503–2509 (2012).
15. Powell, R. J. et al. Results of a double-blind placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation. 118, 58–65 (2008).
16. Sanada, F. et al. Negative action of hepatocyte growth factor/c-met system on angiotensin ii signaling via ligand-dependent epithelial growth factor receptor degradation mechanism in vascular smooth muscle cells. Circ. Res. 105, 667–675 (2009).
22. Sanada, F. et al. Hepatocyte growth factor, but not vascular endothelial growth factor, attenuates angiotensin II-induced endothelial progenitor cell senescence. *Hypertension*, **53**, 77–82 (2009).

23. Uehara, Y. et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. *Nature* **373**, 702–5 (1995).

24. Schmidt, C. et al. Scatter factor/hepatocyte growth factor is essential for liver development. *Nature* **373**, 699–702 (1995).

25. DeFronzo, R. A. & Tripathy, D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. *Diabetes Care* **32**, S157–63 (2009). Review.

26. Samuel, V. T. et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. *J Biol Chem* **279**, 32345–53.21 (2004).

27. Guilherme, A., Virbasius, J. V., Puri, V. & Czech, M. P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. *Nat Rev Mol Cell Biol* **9**, 367–77 (2008). Review.

28. Olefsky, J. M. & Glass, C. K. Macrophages, inflammation, and insulin resistance. *Annu Rev Physiol* **72**, 219–46 (2010). Review.

29. Bell, I. N. et al. Adipose tissue production of hepatocyte growth factor contributes to elevated serum HGF in obesity. *Am J Physiol Endocrinol Metab* **291**, E843–8 (2006).

30. Faber, D. R. et al. Adipose tissue quantity and composition contribute to adipokine concentrations in the subclavian vein and the inferior mesenteric vein. *Int J Obes (Lond)* **36**, 1078–85 (2012).

31. Kusunoki, H., Taniyama, Y., Otsu, R., Rakugi, H. & Morishita, R. Anti-inflammatory effects of hepatocyte growth factor on the vicious cycle of macrophages and adipocytes. *Hypertens Res* **37**, 500–6 (2014).

32. Sanchez-Encinales, V., Cozar-Castellano, L., Garcia-Ocaña, A. & Perdomo, G. Targeted delivery of HGF to the skeletal muscle improves glucose homeostasis in diet-induced obese mice. *J Physiol Biochem* **71**, 795–805 (2015).

33. Falafitis, A. et al. A hepatocyte growth factor receptor (Met)-inulin receptor hybrid governs hepatic glucose metabolism. *Nat Med* **17**, 1577–84 (2011).

34. Fisher, F. M. et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. *Genes Dev* **26**, 271–81 (2012).

35. Li, Y. et al. hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. *J Am Soc Nephrol* **17**, 54–65 (2006).

36. Kusunoki, H. et al. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade. *Hypertension* **59**, 308–16 (2012).

37. Hu, Z. P. et al. Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARγ pathway. *Fundam Clin Pharmacol* **28**, 501–11 (2014).

38. Kusunoki, H., Taniyama, Y., Rakugi, H. & Morishita, R. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptor-γ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension. *J Am Heart Assoc* **2**, e00103 (2013).

39. Wada, T. et al. Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions. *Eur J Pharmacol* **707**, 120–9 (2013).

40. Sanada, F. et al. Induction of Angiogenesis by a Type III Phosphodiesterase Inhibitor, Cilostazol, Through Activation of Peroxisome Proliferator-Activated Receptor-γ and cAMP Pathways in Vascular Cells. *Arterioscler Thromb Vasc Biol* **36**, 545–52 (2016).

Acknowledgements

We would like to thank Blure May Kanako and Rie Shibata for their technical support and all of the members of the Clinical Gene Therapy group at the Osaka University Graduate School of Medicine. This work was partially supported by a Grant-in-Aid from the Organization for Pharmaceutical Safety and Research, a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology from the Japanese government. Department of Clinical Gene Therapy is sponsored by Rohto, Fanci, Saisei Mirai, Novartis, Boehringer Ingelheim, Shionogi, and Anges MG as an endowed chair and funded research department. The commissioned research fund was supported by Rohto, Fanci, Saisei Mirai, Novartis, Boehringer Ingelheim, Shionogi, and Anges MG during past 3 years. The grants and endowment was supported by Astellas, MSD, Daiichi-Sankyo, Tanabe-Mitsubishi, Nikko, Takeda, Novartis, Anges MG, POC Clinical Research, and Bayer during past 3 years. The lecture fee for R.M. was sponsored by Teceda, Boehringer Ingelheim, Daiichi-Sankyo, Astellas, Tanabe-Mitsubishi, Shionogi, MSD, Novartis, AstraZeneca, and Bayer during past 3 years. The commission research grant for Department of Geriatric and General Medicine was supported by Novartis during past 3 years. The grants endowment for Department of Geriatric and General Medicine was supported by Daiichi-Sankyo, MSD, Otsuka, KISSEI, KYOWA KIRIN, Shionogi, Daiichi-Sankyo, Sumitomo Dainihon, Takeda, Tanabe-Mitsubishi, TEIJIN, Boehringer Ingelheim, Novartis, Bayer, Pfizer, and Mochida during past 3 years.

Author Contributions

J.M., M.I., and F.S. designed and performed the experiments. R.O. performed the experiments and analyzed data. Y.T., H.R., and R.M. supervised the experiments.

Additional Information

Supplementary information accompanies this paper at doi:10.1038/s41598-017-00199-4

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017